{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,27]],"date-time":"2025-12-27T07:28:39Z","timestamp":1766820519871,"version":"build-2065373602"},"reference-count":15,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2016,8,1]],"date-time":"2016-08-01T00:00:00Z","timestamp":1470009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,8,1]],"date-time":"2016-08-01T00:00:00Z","timestamp":1470009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1016\/j.clml.2016.04.011","type":"journal-article","created":{"date-parts":[[2016,5,9]],"date-time":"2016-05-09T23:04:41Z","timestamp":1462835081000},"page":"429-433","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Clinical Implications of CD30 Expression in Aggressive B-Cell Lymphomas"],"prefix":"10.1016","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2706-1984","authenticated-orcid":false,"given":"Jozef","family":"Malysz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Erdman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeremy","family":"Klapper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junjia","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Creer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael G.","family":"Bayerl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2016.04.011_bib1","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1097\/CCO.0b013e32834bb8a7","article-title":"CD30-targeted antibody therapy","volume":"23","author":"Younes","year":"2011","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.clml.2016.04.011_bib2","doi-asserted-by":"crossref","first-page":"6428","DOI":"10.1158\/1078-0432.CCR-11-0488","article-title":"Brentuximab vedotin (SGN-35)","volume":"17","author":"Katz","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2016.04.011_bib3","doi-asserted-by":"crossref","first-page":"475","DOI":"10.2217\/imt.11.15","article-title":"Brentuximab vedotin for the treatment of CD30+ lymphomas","volume":"3","author":"Foyil","year":"2011","journal-title":"Immunotherapy"},{"key":"10.1016\/j.clml.2016.04.011_bib4","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1358\/dot.2012.48.4.1788435","article-title":"Brentuximab vedotin: its role in the treatment of anaplastic large cell and Hodgkin's lymphoma","volume":"48","author":"Haddley","year":"2012","journal-title":"Drugs Today (Barc)"},{"year":"2008","series-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tisues","key":"10.1016\/j.clml.2016.04.011_bib5"},{"key":"10.1016\/j.clml.2016.04.011_bib6","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1182\/blood-2012-10-461848","article-title":"CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study","volume":"121","author":"Hu","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2016.04.011_bib7","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1023\/A:1011195708834","article-title":"Among diffuse large B-cell lymphomas, T-cell-rich\/histiocyte-rich BCL and CD30+ anaplastic B-cell subtypes exhibit distinct clinical features","volume":"12","author":"Maes","year":"2001","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2016.04.011_bib8","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1080\/10428190902725813","article-title":"Epstein-Barr virus positive diffuse large B-cell lymphoma of the elderly","volume":"50","author":"Wong","year":"2009","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2016.04.011_bib9","doi-asserted-by":"crossref","first-page":"4726","DOI":"10.1182\/blood-2010-12-323238","article-title":"Age-related EBV-associated lymphoproliferative disorders in the Western population: a spectrum of reactive lymphoid hypeplasia and lymphoma","volume":"117","author":"Dojcinov","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2016.04.011_bib10","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.3109\/10428194.2013.778407","article-title":"Frequency and extent of CD30 expression in diffuse large B-cell lymphoma and its relation to clinical and biologic factors: a retrospective study of 167 cases","volume":"54","author":"Campuzano-Zuluaga","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2016.04.011_bib11","first-page":"112","article-title":"A\u00a0clinicopathologic and immunohistochemical study of diffuse large B-cell lymphoma","volume":"31","author":"Tao","year":"2002","journal-title":"Zhongua Bing Li Xue Za Zhi"},{"key":"10.1016\/j.clml.2016.04.011_bib12","first-page":"416","article-title":"The pattern of CD15, CD30 and BCL-2 expression in diffuse large B-cell lymphoma","volume":"61","author":"Eow","year":"2006","journal-title":"Med J Malaysia"},{"key":"10.1016\/j.clml.2016.04.011_bib13","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1200\/JCO.1999.17.5.1474","article-title":"Estrogen Receptor Status by Immunohistochemistry Is Superior to the Ligant-Binding Assay for Predicting Response to Adjuvant Endocrine Therapy in Breast Cancer","volume":"17","author":"Harvey","year":"1999","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2016.04.011_bib14","first-page":"183","article-title":"Brentuximab vendotin and diffuse large B-cell lymphoma","volume":"3","author":"Gandhi","year":"2015","journal-title":"J\u00a0Hematol Thromb Dis"},{"key":"10.1016\/j.clml.2016.04.011_bib15","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1182\/blood-2014-09-598763","article-title":"Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed\/refractory DLBCL with variable CD30 expression","volume":"125","author":"Eric","year":"2015","journal-title":"Blood"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265016300544?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265016300544?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:27:35Z","timestamp":1761870455000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265016300544"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8]]},"references-count":15,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2016,8]]}},"alternative-id":["S2152265016300544"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2016.04.011","relation":{},"ISSN":["2152-2650"],"issn-type":[{"type":"print","value":"2152-2650"}],"subject":[],"published":{"date-parts":[[2016,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical Implications of CD30 Expression in Aggressive B-Cell Lymphomas","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2016.04.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}